Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Clinical studies with the Abl tyrosine kinase inhibitor STI-571 in chronic myeloid leukemia demonstrate that many patients with advanced stage disease respond initially but then relapse. Through biochemical and molecular analysis of clinical material, we find that drug resistance is associated with the reactivation of BCR-ABL signal transduction in all cases examined. In six of nine patients, resistance was associated with a single amino acid substitution in a threonine residue of the Abl kinase domain known to form a critical hydrogen bond with the drug. This substitution of threonine with isoleucine was sufficient to confer STI-571 resistance in a reconstitution experiment. In three patients, resistance was associated with progressive BCR-ABL gene amplification. These studies provide evidence that genetically complex cancers retain dependence on an initial oncogenic event and suggest a strategy for identifying inhibitors of STI-571 resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast to some targeted therapies for which dominant mechanisms of resistance have been observed, such as BCR-ABL mutations that cause resistance to imatinib in chronic myeloid leukemia,22 KRASG12C-mutant cancers appear to evolve diverse mechanisms of resistance to adagrasib.”
From Acquired Resistance to KRAS G12C Inhibition in Cancer (2021) · cites this paper as [22]
Citations
Cites
Thompson, J. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.24.4876 · Cited by 38,993
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Self-citationEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Self-citationStructural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780
Daley, G. Q., Van Etten, R. A., & Baltimore, D. (1990) · Science · doi:10.1126/science.2406902 · Cited by 1,756
Sawyers, C. L. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401706 · Cited by 1,621
Self-citationThe Biology of Chronic Myeloid Leukemia
Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R., & Kantarjian, H. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907153410306 · Cited by 1,302
Reversible Tumorigenesis by MYC in Hematopoietic Lineages
Felsher, D. W., & Bishop, J. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80367-6 · Cited by 881
Essential role for oncogenic Ras in tumour maintenance
Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. (1999) · Nature · doi:10.1038/22788 · Cited by 875
Cited by
Items 401–500 of 1,008
Soverini, S., Gnani, A., Colarossi, S., Castagnetti, F., Abruzzese, E., Paolini, S., Merante, S., Orlandi, E., de Matteis, S., Gozzini, A., et al. (2009) · Blood · doi:10.1182/blood-2009-01-197186 · Cited by 175
Noguchi, K., Katayama, K., & Sugimoto, Y. (2014) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s38295 · Cited by 167
“Resistance to this drug is typically conferred by mutations in the target kinase within the region of the drug–kinase interaction, 79–82 but another mechanism leading to imatinib resistance correlates with ABCB1/P-gp expression.”
The origins of cancer robustness and evolvability
Tian, T., Olson, S., Whitacre, J. M., & Harding, A. (2011) · Integr. Biol. · doi:10.1039/c0ib00046a · Cited by 169
Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia
de Beauchamp, L., Himonas, E., & Helgason, G. V. (2022) · Leukemia · doi:10.1038/s41375-021-01416-w · Cited by 168
“This is exemplified by cells carrying point mutations on the BCR-ABL or FLT3-TKD genes, which are de facto resistant to TKI treatment [27, 28], and by resistance to BCL-2 inhibitor venetoclax [29] or to standard chemotherapy [30, 31] in AML.”
BackgroundPaclitaxel Nanocrystals for Overcoming Multidrug Resistance in Cancer
Liu, Y., Huang, L., & Liu, F. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100012s · Cited by 168
“Generally speaking, when tumors develop resistance to a certain drug (about 50% of total cancer cases) [19], physicians have to switch to another chemotherapeutic agent or radiation to circumvent this resistance.”
BackgroundZhou, J., Bi, C., Janakakumara, J. V., Liu, S.-C., Chng, W.-J., Tay, K.-G., Poon, L.-F., Xie, Z., Palaniyandi, S., Yu, H., et al. (2009) · Blood · doi:10.1182/blood-2008-05-156422 · Cited by 162
Cancer Stem Cells: Are We Missing the Target?
Jones, R. J., Matsui, W. H., & Smith, B. D. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh095 · Cited by 169
Converting Cancer Therapies into Cures: Lessons from Infectious Diseases
Glickman, M. S., & Sawyers, C. L. (2012) · Cell · doi:10.1016/j.cell.2012.02.015 · Cited by 168
Self-citationSensitization of Drug Resistant Cancer Cells: A Matter of Combination Therapy
Leary, M., Heerboth, S., Lapinska, K., & Sarkar, S. (2018) · Cancers · doi:10.3390/cancers10120483 · Cited by 165
“Mutations in the imatinib binding site inhibit the action of the drug while preserving the function of the fusion protein [38,54].”
BackgroundMaloney, E., Clark, C., Sivakumar, H., Yoo, K., Aleman, J., Rajan, S. A. P., Forsythe, S., Mazzocchi, A., Laxton, A. W., Tatter, S. B., et al. (2020) · Micromachines · doi:10.3390/mi11020208 · Cited by 161
“Failure to respond to treatment as well as drug resistance to anti-cancer drugs are critical challenges in clinical oncology that can be ascribed to factors like genetic mutation [3–5], oncogenic amplification [6,7], and other changes in the tumor cell machinery that result in changes in the uptake capability, metabol…”
BackgroundOpportunities and challenges in the development of kinase inhibitor therapy for cancer
Sawyers, C. L. (2003) · Genes & Development · doi:10.1101/gad.1152403 · Cited by 170
“In a few cases, the explanation of how the mutation causes drug resistance is straightforward, because GENES & DEVELOPMENT 3005 the nucleotide change alters an amino acid that makes direct contact with the drug (Gorre et al. 2001).”
BackgroundSelf-citationWu, J., Meng, F., Kong, L.-Y., Peng, Z., Ying, Y., Bornmann, W. G., Darnay, B. G., Lamothe, B., Sun, H., Talpaz, M., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn188 · Cited by 165
Mechanisms of Acquired Resistance to Targeted Cancer Therapies
Lackner, M. R., Wilson, T. R., & Settleman, J. (2012) · Future Oncology · doi:10.2217/fon.12.86 · Cited by 164
“BCR–ABL Imatinib, nilotinib CML Secondary BCR–ABL mutations, BCR–ABL amplification, P-glycoprotein, MDR, LYN [65–69]”
BackgroundInteraction of Imatinib Mesilate with Human P-Glycoprotein
Hamada, A., Miyano, H., Watanabe, H., & Saito, H. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.055574 · Cited by 162
“…might involve a point mutation in the Bcr-Abl kinase domain, amplification of the Bcr-Abl gene or protein, binding of imatinib mesilate to -acid glycoprotein, efflux of the drug mediated by P-gp, or inactiva- tion by glutathione (le Coutre et al., 2000; Mahon et al., 2000; Gorre et al., 2001).”
BackgroundKinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies
Bikker, J. A., Brooijmans, N., Wissner, A., & Mansour, T. S. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm8010542 · Cited by 166
Jabbour, E., Kantarjian, H., & Cortes, J. (2015) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2015.03.006 · Cited by 164
Protein kinase biochemistry and drug discovery
Schwartz, P. A., & Murray, B. W. (2011) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2011.07.004 · Cited by 210
Dorer, D. J., Knickerbocker, R. K., Baccarani, M., Cortes, J. E., Hochhaus, A., Talpaz, M., & Haluska, F. G. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.07.007 · Cited by 166
Mnk kinase pathway: Cellular functions and biological outcomes
Joshi, S. (2014) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v5.i3.321 · Cited by 159
Analysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571
Corbin, A. S., Buchdunger, E., Pascal, F., & Druker, B. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111525200 · Cited by 162
Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588
le Coutre, P., Kreuzer, K.-A., Pursche, S., v. Bonin, M., Leopold, T., Baskaynak, G., Dörken, B., Ehninger, G., Ottmann, O., Jenke, A., et al. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0741-6 · Cited by 161
“Especially in view of the various mechanisms of resistance to imatinib that have been described so far [16, 17, 18], precise pharmacokinetic data in relation to clinical response are needed, as in a significant number of non-responders none of the underlying mechanisms of resistance can be identified.”
BackgroundSecondary mutations as mediators of resistance to targeted therapy in leukemia
Daver, N. G., Cortes, J. E., Ravandi, F., Patel, K. P., Burger, J. A., Konopleva, M. Y., & Kantarjian, H. M. (2015) · Blood · doi:10.1182/blood-2014-10-605808 · Cited by 170
“A frequent mechanism of resistance to imatinib is the occurrence of point mutations in the Bcr-Abl KD, although Bcr-Abl amplification and impaired signaling pathways may contribute to the resistance.(98) Other possible Bcr-Abl independent mechanisms that incite resistance include reduced bioavailability of imatinib wi…”
BackgroundQuintas-Cardama, A., Kantarjian, H., Jones, D., Nicaise, C., O'Brien, S., Giles, F., Talpaz, M., & Cortes, J. (2007) · Blood · doi:10.1182/blood-2006-07-035493 · Cited by 164
Chu, S., Holtz, M., Gupta, M., & Bhatia, R. (2004) · Blood · doi:10.1182/blood-2003-04-1271 · Cited by 163
Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia
Bixby, D., & Talpaz, M. (2011) · Leukemia · doi:10.1038/leu.2010.238 · Cited by 162
Soverini, S., De Benedittis, C., Machova Polakova, K., Brouckova, A., Horner, D., Iacono, M., Castagnetti, F., Gugliotta, G., Palandri, F., Papayannidis, C., et al. (2013) · Blood · doi:10.1182/blood-2013-03-487728 · Cited by 163
“Soon after, however, it was observed that BCR-ABL kinase domain (KD) mutated forms with reduced or no sensitivity to imatinib could be selected.(2) Second-(dasatinib/nilotinib/bosutinib) and third-generation (ponatinib) TKIs with much fewer insensitive mutations are now already approved or pending approval (Table 1(3-…”
BackgroundGarg, R. J., Kantarjian, H., O'Brien, S., Quintás-Cardama, A., Faderl, S., Estrov, Z., & Cortes, J. (2009) · Blood · doi:10.1182/blood-2009-05-221531 · Cited by 164
Structure, Regulation, Signaling, and Targeting of Abl Kinases in Cancer
Hantschel, O. D. (2012) · Genes & Cancer · doi:10.1177/1947601912458584 · Cited by 180
Pharmacogenetics-based therapeutic recommendations — ready for clinical practice?
Kirchheiner, J., Fuhr, U., & Brockmöller, J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1801 · Cited by 160
Pharmacodynamic Biomarkers for Molecular Cancer Therapeutics
(2006) · Advances in Cancer Research · doi:10.1016/s0065-230x(06)96008-4 · Cited by 161
Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias
Jaiswal, S., Traver, D., Miyamoto, T., Akashi, K., Lagasse, E., & Weissman, I. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1633833100 · Cited by 161
Manley, P. W., Cowan-Jacob, S. W., & Mestan, J. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.07.040 · Cited by 160
“Following the initial observation of T315I Bcr-Abl, currently over 35 such mutant forms of the enzyme have been observed in CML patients [6,7].”
BackgroundInfluentialMelo, J. V., Hughes, T. P., & Apperley, J. F. (2003) · Hematology · doi:10.1182/asheducation-2003.1.132 · Cited by 204
“Screening for BCR-ABL Mutations The emergence of clones with mutated BCR-ABL is a common cause of resistance in patients with advanced phase CML and those in late chronic phase ( Table 1).(13,14,16,72-75,97) It is too early to determine whether mutations will emerge as a common problem for patients treated in early ch…”
BackgroundUsing transcriptome sequencing to identify mechanisms of drug action and resistance
Wacker, S. A., Houghtaling, B. R., Elemento, O., & Kapoor, T. M. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.779 · Cited by 160
Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases.
Wisniewski, D. J., Lambek, C. L., Liu, C., Strife, A., Veach, D. R., Nagar, B., Young, M. A., Schindler, T. H., Bornmann, W. G., Bertino, J. R., et al. (2002) · PubMed · Cited by 174
EGFR and erbB2 mutation status in Japanese lung cancer patients
Sasaki, H., Shimizu, S., Endo, K., Takada, M., Kawahara, M., Tanaka, H., Matsumura, A., Iuchi, K., Haneda, H., Suzuki, E., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21301 · Cited by 164
“Threonine 315 to isoleucine substitution in the Abl kinase domain was a critical structural determinant controlling inhibitor sensitivity of STI571.”
BackgroundInfluentialSystems biology approaches for advancing the discovery of effective drug combinations
Ryall, K. A., & Tan, A. C. (2015) · Journal of Cheminformatics · doi:10.1186/s13321-015-0055-9 · Cited by 159
“In cancer, drug resistance can occur through mutation of the drug target [11], amplification of an alternate pathway [12], or intrinsic resistance of a subset of the cancer cells [13].”
Backgroundvon Bubnoff, N., Manley, P. W., Mestan, J., Sanger, J., Peschel, C., & Duyster, J. (2006) · Blood · doi:10.1182/blood-2005-12-010132 · Cited by 163
“Clinical resistance to imatinib has been attributed to amplification of the Bcr-Abl gene,(8,9) clonal evolution,(9-13) and most importantly, Bcr-Abl gene mutations that obviate binding to the drug target.(8,14-19) Consequently, alternative Bcr-Abl kinase inhibitors, such as PD166326, nilotinib (AMN107) or dasatinib (B…”
BackgroundGatekeeper Mutations Mediate Resistance to BRAF-Targeted Therapies
Whittaker, S., Kirk, R., Hayward, R., Zambon, A., Viros, A., Cantarino, N., Affolter, A., Nourry, A., Niculescu-Duvaz, D., Springer, C., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000758 · Cited by 156
“Notably, an isoleucine for threonine substitution of the gatekeeper in BCR-ABL mediates imatinib resistance in chronic myelogenous leukemia (28).”
BackgroundJanus Kinase 2: A Critical Target in Chronic Myelogenous Leukemia
Samanta, A. K., Lin, H., Sun, T., Kantarjian, H. M., & Arlinghaus, R. B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0025 · Cited by 157
“We propose that Jak2 may be a target for treatment of CML patients, especially those who are resistant to imatinib because AG490 treatment of hematopoietic cells transformed by imatinib-resistant mutants of Bcr-Abl (15) was induced to undergo apoptosis (Fig.”
BackgroundGodin-Heymann, N., Bryant, I., Rivera, M. N., Ulkus, L., Bell, D. W., Riese, D. J., Settleman, J., & Haber, D. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4625 · Cited by 155
“(T315I) in Gleevec-resistant BCR-ABL (12).”
BackgroundInfluentialBRAF as a potential therapeutic target in melanoma and other malignancies
Tuveson, D. A., Weber, B. L., & Herlyn, M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00189-2 · Cited by 157
“As predicted, the responsiveness of CML and GIST patients to Gleevec directly correlates with the inhibition of the tyrosine kinase activity of Bcr-Abl and mutant KIT, respectively (Gorre et al., 2001; Tuveson et al., 2001).”
BackgroundAnticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy
Raschi, E., Vasina, V., Ursino, M. G., Boriani, G., Martoni, A., & De Ponti, F. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.10.002 · Cited by 150
“The imatinibresistant mutant ABL T315I was found to rescue cells from imatinibinduced toxicity hence supporting ABL as an important antitarget for cardiac damage (Gorre et al., 2001).”
BackgroundJabbour, E., Kantarjian, H. M., Jones, D., Shan, J., O'Brien, S., Reddy, N., Wierda, W. G., Faderl, S., Garcia-Manero, G., Verstovsek, S., et al. (2009) · Blood · doi:10.1182/blood-2008-04-154344 · Cited by 155
“Median follow-up from imatinib escalation, mo 61 (7-89)”
BackgroundPathogenic B‐cell receptor signaling in lymphoid malignancies: New insights to improve treatment
Young, R. M., Phelan, J. D., Wilson, W. H., & Staudt, L. M. (2019) · Immunological Reviews · doi:10.1111/imr.12792 · Cited by 173
Alterations of androgen receptor in prostate cancer
Linja, M. J., & Visakorpi, T. (2004) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2004.10.012 · Cited by 177
Using ancient protein kinases to unravel a modern cancer drug’s mechanism
Wilson, C., Agafonov, R. V., Hoemberger, M., Kutter, S., Zorba, A., Halpin, J., Buosi, V., Otten, R., Waterman, D., Theobald, D. L., et al. (2015) · Science · doi:10.1126/science.aaa1823 · Cited by 155
Hadzijusufovic, E., Albrecht-Schgoer, K., Huber, K., Hoermann, G., Grebien, F., Eisenwort, G., Schgoer, W., Herndlhofer, S., Kaun, C., Theurl, M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.245 · Cited by 160
Branford, S., Rudzki, Z., Harper, A., Grigg, A., Taylor, K. F., Durrant, S., Arthur, C., Browett, P., Schwarer, A. P., David, D. F., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403158 · Cited by 154
Hsp90: an emerging target for breast cancer therapy
Beliakoff, J., & Whitesell, L. J. (2004) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000136876.11928.be · Cited by 176
Molecular monitoring of BCR–ABL as a guide to clinical management in chronic myeloid leukaemia
Hughes, T., & Branford, S. (2006) · Blood Reviews · doi:10.1016/j.blre.2005.01.008 · Cited by 158
Giuriato, S., Ryeom, S., Fan, A. C., Bachireddy, P., Lynch, R. C., Rioth, M. J., van Riggelen, J., Kopelman, A. M., Passegué, E., Tang, F., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608017103 · Cited by 149
Amit, S., & Ben‐Neriah, Y. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00096-2 · Cited by 160
Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis
Huang, D., Zhou, T., Lafleur, K., Nevado, C., & Caflisch, A. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp650 · Cited by 169
Peng, C., Brain, J. M., Hu, Y., Goodrich, A., Kong, L., Grayzel, D., Pak, R. H., Read, M. A., & Li, S. (2007) · Blood · doi:10.1182/blood-2006-10-054098 · Cited by 155
Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas
Bisserier, M., & Wajapeyee, N. (2018) · Blood · doi:10.1182/blood-2017-08-804344 · Cited by 160
Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571
Klejman, A., Rushen, L., Morrione, A., Słupianek, A., & Skórski, T. (2002) · Oncogene · doi:10.1038/sj.onc.1205724 · Cited by 160
Levinson, N. M., & Boxer, S. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029828 · Cited by 148
“Despite the success of imatinib in treating CML, some patients ultimately develop resistance to imatinib treatment and undergo clinical relapse [5].”
BackgroundO’Hare, T., Deininger, M. W., Eide, C. A., Clackson, T., & Druker, B. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3314 · Cited by 150
“Studies of relapsed patients revealed that BCR-ABL signaling is often reactivated at the time of resistance (34).”
BackgroundKhorashad, J. S., Anand, M., Marin, D., Saunders, S., Al-Jabary, T., Iqbal, A., Margerison, S., Melo, J. V., Goldman, J. M., Apperley, J. F., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404137 · Cited by 149
K252a inhibits the oncogenic properties of Met, the HGF receptor
Morotti, A., Mila, S., Accornero, P., Tagliabue, E., & Ponzetto, C. (2002) · Oncogene · doi:10.1038/sj.onc.1205622 · Cited by 158
“In this case, hitting more than one target kinase in the same neoplastic cell may ultimately be advantageous, both in terms of eliminating possible alternative pathways which could drive malignancy, and of reducing the chances of developing resistance to the drug (Gorre et al., 2001).”
BackgroundWare, K. E., Marshall, M. E., Heasley, L. R., Marek, L., Hinz, T. K., Hercule, P., Helfrich, B. A., Doebele, R. C., & Heasley, L. E. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014117 · Cited by 146
“within the Abl coding sequence [6,7] that renders imatinib ineffective.”
BackgroundWhite, D. L., Saunders, V. A., Lyons, A. B., Branford, S., Grigg, A., To, L. B., & Hughes, T. P. (2005) · Blood · doi:10.1182/blood-2005-03-1103 · Cited by 155
Baker, K. S., Gurney, J. G., Ness, K. K., Bhatia, R., Forman, S. J., Francisco, L., McGlave, P. B., Robison, L. L., Snyder, D., Weisdorf, D. J., et al. (2004) · Blood · doi:10.1182/blood-2004-03-1010 · Cited by 148
Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells
Poh, A. R., O’Donoghue, R. J. J., & Ernst, M. (2015) · Oncotarget · doi:10.18632/oncotarget.4199 · Cited by 159
“methionine) at this position can confer clinical resistance, as exemplified in acquired resistance to Imatinib, Gefitinib or Erlotinib [118–121].”
BackgroundWang, Y., Cai, D., Brendel, C., Barett, C., Erben, P., Manley, P. W., Hochhaus, A., Neubauer, A., & Burchert, A. (2007) · Blood · doi:10.1182/blood-2006-08-040022 · Cited by 143
Establishment of a human non‐small cell lung cancer cell line resistant to gefitinib
Koizumi, F., Shimoyama, T., Taguchi, F., Saijo, N., & Nishio, K. (2005) · International Journal of Cancer · doi:10.1002/ijc.20985 · Cited by 157
Amit, I., Wides, R., & Yarden, Y. (2007) · Molecular Systems Biology · doi:10.1038/msb4100195 · Cited by 142
Salesse, S., & Verfaillie, C. M. (2002) · Oncogene · doi:10.1038/sj.onc.1206082 · Cited by 176
“Clinically, the majority of patients who relapse after an initial response to STI571 have reactivation of the BCR/ABL kinase (Gorre et al., 2001).”
BackgroundInfluentialFridman, J. S., Caulder, E., Hansbury, M., Liu, X., Yang, G., Wang, Q., Lo, Y., Zhou, B.-B., Pan, M., Thomas, S. M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2116 · Cited by 145
Mizuno, K., Lambert, S., Baldacci, G., Murray, J. M., & Carr, A. M. (2009) · Genes & Development · doi:10.1101/gad.1863009 · Cited by 136
“2004), while the amplification of genes involved in drug metabolism is a common mechanism by which tumor cells acquire chemotherapy resistance (Gorre et al. 2001).”
BackgroundFumo, G., Akin, C., Metcalfe, D. D., & Neckers, L. (2003) · Blood · doi:10.1182/blood-2003-07-2477 · Cited by 155
Emerson, R. O., Sherwood, A. M., Rieder, M. J., Guenthoer, J., Williamson, D. W., Carlson, C. S., Drescher, C. W., Tewari, M., Bielas, J. H., & Robins, H. S. (2013) · The Journal of Pathology · doi:10.1002/path.4260 · Cited by 145
Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development
Kamath, S., & Buolamwini, J. K. (2006) · Medicinal Research Reviews · doi:10.1002/med.20070 · Cited by 152
Molecular tumour boards — current and future considerations for precision oncology
Tsimberidou, A. M., Kahle, M., Vo, H. H., Baysal, M. A., Johnson, A., & Meric-Bernstam, F. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00824-4 · Cited by 144
Blencke, S., Zech, B., Engkvist, O., Greff, Z., Őrfi, L., Horváth, Z., Kéri, G., Ullrich, A., & Daub, H. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.02.029 · Cited by 153
Fiskus, W., Pranpat, M., Bali, P., Balasis, M., Kumaraswamy, S., Boyapalle, S., Rocha, K., Wu, J., Giles, F., Manley, P. W., et al. (2006) · Blood · doi:10.1182/blood-2005-11-4639 · Cited by 145
The emergence of drug resistance to targeted cancer therapies: Clinical evidence
Sarmento‐Ribeiro, A. B., Scorilas, A., Gonçalves, A. C., Efferth, T., & Trougakos, I. P. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100646 · Cited by 149
Wang, L., Pearson, K., Ferguson, J. E., & Clark, R. E. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04200.x · Cited by 148
“This substitution was shown to confer imatinib resistance in a reconstitution experiment (Gorre et al, 2001).”
BackgroundDeMatteo, R. P. (2002) · Annals of Surgical Oncology · doi:10.1007/bf02557518 · Cited by 156
Moen, M. D., McKeage, K., Plosker, G. L., & Siddiqui, M. A. A. (2007) · Drugs · doi:10.2165/00003495-200767020-00010 · Cited by 144
du Manoir, J. M., Francia, G., Man, S., Mossoba, M. E., Medin, J. A., Viloria‐Petit, A., Hicklin, D. J., Emmenegger, U., & Kerbel, R. S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1109 · Cited by 151
Bcr–Abl variants: biological and clinical aspects
Advani, A. S., & Pendergast, A. M. (2002) · Leukemia Research · doi:10.1016/s0145-2126(01)00197-7 · Cited by 175
Chronic Myeloid Leukemia Stem Cells
Kavalerchik, E., Goff, D., & Jamieson, C. H. M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5745 · Cited by 138
“This phenomenon was documented in some patients with acquired resistance.(34) However, the more common causes of TKI resistance have been clonal evolution present in up to a quarter of patients on disease progression(35) and mutations of the BCR-ABL.”
BackgroundManagement of imatinib-resistant patients with chronic myeloid leukemia
Bhamidipati, P. K., Kantarjian, H. M., Cortes, J. E., Cornelison, A. M., & Jabbour, E. J. (2012) · Therapeutic Advances in Hematology · doi:10.1177/2040620712468289 · Cited by 158
Betulinic acid in the treatment of tumour diseases: Application and research progress
Jiang, W., Li, X., Dong, S., & Zhou, W. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111990 · Cited by 151
Wohlbold, L., van der Kuip, H., Miething, C., Vornlocher, H., Knabbe, C., Duyster, J., & Aulitzky, W. E. (2003) · Blood · doi:10.1182/blood-2002-12-3899 · Cited by 153
25 Years of Small Molecular Weight Kinase Inhibitors: Potentials and Limitations
Fabbro, D. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.095489 · Cited by 152
Structure of the Bcr-Abl oncoprotein oligomerization domain.
Zhao, X., Ghaffari, S., Lodish, H. F., Malashkevich, V. N., & Kim, P. S. (2002) · PubMed · doi:10.1038/nsb747 · Cited by 145
Eiring, A. M., Page, B. D. G., Kraft, I. L., Mason, C. C., Vellore, N. A., Resetca, D., Zabriskie, M. S., Zhang, T. Y., Khorashad, J. S., Engar, A. J., et al. (2015) · Leukemia · doi:10.1038/leu.2014.245 · Cited by 131
Skora, L., Mestan, J., Fabbro, D., Jahnke, W., & Grzesiek, S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314712110 · Cited by 138
“However, spontaneous point mutations render these inhibitors ineffective and cause clinical relapse in advanced-phase patients (12, 13).”
BackgroundTiedt, R., Degenkolbe, E., Furet, P., Appleton, B. A., Wagner, S., Schoepfer, J. G., Buck, E., Ruddy, D. A., Monahan, J. E., Jones, M. D., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4433 · Cited by 139
“This is particularly well documented in the case of CML therapy with imatinib, where multiple mutations in the target protein Bcr-Abl conferring various degrees of resistance have been isolated from patients (1, 2).”
BackgroundInstability of BCR-ABL Gene in Primary and Cultured Chronic Myeloid Leukemia Stem Cells
Jiang, X., Saw, K. M., Eaves, A., & Eaves, C. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk150 · Cited by 137
Oki, Y., Kantarjian, H. M., Gharibyan, V., Jones, D., O'Brien, S., Verstovsek, S., Cortes, J., Morris, G. M., Garcia‐Manero, G., & Issa, J. J. (2007) · Cancer · doi:10.1002/cncr.22470 · Cited by 136
Polak, R., & Buitenhuis, M. (2011) · Blood · doi:10.1182/blood-2011-07-366203 · Cited by 150
The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Pophali, P. A., & Patnaik, M. M. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000165 · Cited by 146
Wilson, M. B., Schreiner, S. J., Choi, H.-J., Kamens, J., & Smithgall, T. E. (2002) · Oncogene · doi:10.1038/sj.onc.1206008 · Cited by 151
“CrkL is a direct substrate for Bcr –Abl in CML cells and serves as useful endogenous reporter of Bcr –Abl tyrosine kinase activity (Senechal et al., 1996; Oncogene Sattler and Salgia, 1998; Gorre et al., 2001).”
BackgroundMethodInfluentialPunchihewa, C., Inoue, A., Hishiki, A., Fujikawa, Y., Connelly, M., Evison, B., Shao, Y., Heath, R., Kuraoka, I., Rodrigues, P., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.353201 · Cited by 135
“However, there is a high risk of resistance based onmutation of the pathway components targeted, as seen in mutations of BCR-ABL by imatinib (2) and of SMO by vismodegib (3).”
BackgroundChronic myeloid leukemia: reminiscences and dreams
Mughal, T. I., Radich, J. P., Deininger, M. W., Apperley, J. F., Hughes, T. P., Harrison, C. J., Gambacorti-Passerini, C. B., Saglio, G. N., Cortes, J. E., & Daley, G. Q. (2016) · Haematologica · doi:10.3324/haematol.2015.139337 · Cited by 145
BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance
Quentmeier, H., Eberth, S., Romani, J., Zaborski, M., & Drexler, H. G. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-6 · Cited by 132
“Causes for imatinib-resistance are (i) the development of cell clones carrying mutations in the kinase domain of BCR-ABL1 [ 3 ,4]; (ii) low intracellular drug levels caused by disordered expression of influx and efflux transporters [5,6]; (iii) overexpression of BCR-ABL1 [7,8]; and (iv) activation of alternative signa…”
Background
Metadata
- Authors
- Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L.
- Affiliations
- University of California, Los Angeles (US)
- Department of Pathology, and
- Department of Medicine,
- Corresponding author
- Sawyers, Charles L.
- Venue
- Science
- Published
- 2001-08-03
- Volume
- 293
- Issue
- 5531
- Pages
- 876-880
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1999614615
- Cited by
- 3,104
- References
- 26
- Citations by year
- 2026: 32 · 2025: 33 · 2024: 45 · 2023: 64 · 2022: 44 · 2021: 60 · 2020: 71 · 2019: 76 · 2018: 68 · 2017: 84 · 2016: 96 · 2015: 106 · 2014: 141 · 2013: 169 · 2012: 162
- FWCI
- 85.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (GM-07185, T32GM007185)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- imatinib, BCR-ABL, chronic myeloid leukemia, drug resistance, Abl tyrosine kinase, BCR-ABL mutations, relapse
- MeSH terms
- Imatinib Mesylate, Amino Acid Sequence, Antineoplastic Agents, Base Sequence, Benzamides, Blast Crisis, Cell Line, Gene Amplification, Humans, Hydrogen Bonding, Molecular Sequence Data, Philadelphia Chromosome, Phosphorylation, Piperazines, Proto-Oncogene Proteins, Pyrimidines, Recurrence, Signal Transduction, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Genes, abl, Proto-Oncogene Proteins c-abl, Point Mutation, Protein Structure, Tertiary, Drug Resistance, Neoplasm, Amino Acid Substitution, Proto-Oncogene Proteins c-crk
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.